Sign In
Buy STRO
$23.57
-0.160 (-0.674%)
At Close: Jul 17, 2026
Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights
04:07pm, Thursday, 13'th Mar 2025
– Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management changes announced as part of transition –
Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline
04:05pm, Thursday, 13'th Mar 2025
– Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner –
Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference
04:05pm, Monday, 03'rd Mar 2025
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format
Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
04:05pm, Tuesday, 07'th Jan 2025
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format
Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless
06:28pm, Thursday, 02'nd Jan 2025
STRO's valuation remains compelling despite recent market hits, with optimism for a turnaround driven by late-stage clinical trials and strong pipeline potential. Luveltamab tazevibulin shows promisin
Sutro Biopharma (STRO) Upgraded to Buy: Here's What You Should Know
01:00pm, Monday, 18'th Nov 2024
Sutro Biopharma (STRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue Estimates
06:41pm, Wednesday, 13'th Nov 2024
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to loss of $0.81 per share a year ago.
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights
04:30pm, Wednesday, 13'th Nov 2024
- Expects to deliver three Investigational New Drug (IND) applications in next three years based on next-generation ADC technology -
Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference
04:05pm, Monday, 04'th Nov 2024
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format
Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum
04:05pm, Thursday, 10'th Oct 2024
Proprietary cell-free platform enables the design of next-generation ADCs intended to broaden addressable patient populations
Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology
12:46pm, Monday, 23'rd Sep 2024
STRO specializes in ADCs for oncology, leveraging XpressCF and XpressCF+ platforms for precise antibody-drug conjugates without living cells. STRO-002, a promising ADC for ovarian cancer, has shown fa
Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 20'th Sep 2024
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
03:00am, Saturday, 14'th Sep 2024
- 4.3 mg/kg of luveltamab tazevibulin (luvelta) in combination with standard dose of bevacizumab (15 mg/kg) every 3 weeks resulted in a 56% objective response rate in patients with late-stage ovarian
Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024
08:00am, Wednesday, 11'th Sep 2024
SOUTH SAN FRANCISCO, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format
